From the June 2017 article:
Super important paragraph here discussing the specific vaccine-specific antibodies in Travelan and IMM-124 that set it apart from regular bovine colostrum and "are believed to provide the basis for the clinical protection afforded by HBC (today's Travelan and, perfected even more - specifically for inflammation - IMM-124E) in ETEC-challenged volunteers, which included reduced rate of illness (sure did...100% protection) and abdominal pain (reference #24 is Tacket's groundbreaking New England Journal of Medicine published study). The authors then go on to discuss other cross-reactive antibodies found in Travelan and IMM-124E that explain why it is effective against Shigella as well (see the Immuron/DoD NHP press release earlier this year).
Carol Tacket, Travelan, and the New England Journal of Medicine, page-9
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.93M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.5¢ | $27.18K | 258.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 320829 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 4965 | 1 |
View Market Depth
| Last trade - 15.38pm 27/09/2024 (20 minute delay) ? |
| IMC (ASX) Chart |